VCAM1 and cancer: This peptide, peptide-5 (p5, for the 5th candidate tested), was shown enable post-formulation lipid membrane editing to enhance efficacy of the nanoparticulate cancer drug DoxilTM (i.e., doxorubicin enveloped in a “stealth “liposome) by enabling direct binding to cancer endothelium and uptake via the VCAM-1 targeting peptide fused to the p5 peptide [34,36,50,161].